TABLE 1.
Phenotype and genotype of MDSCs in human cancer.
| MDSCs | Tumor entity | Sample type | Phenotypic markers | Genotypic markers |
|---|---|---|---|---|
| PMN-MDSCs (Lin− HLA−DR- CD11b+ CD33+ CD15+/CD66b+ | NSCLC, head and neck cancer | PB | LOX1 Condamine and Gabrilovich. (2011); Condamine et al. (2016) | |
| NSCLC | PB | FATP2 Veglia et al. (2019) | ||
| Head and neck cancer | PB | DR5 Condamine et al. (2014) | ||
| Breast cancer | PB | CD84 Alshetaiwi et al. (2020) | WFDC17, CD84, ARG2, IL1B Alshetaiwi et al. (2020) | |
| Multiple myeloma | BM | PTGS2, CSF1, IL-8, IRF1, IL4R, STAT1, STAT3 and STAT6, TGFB1 Perez et al. (2020) | ||
| NSCLC | PB | AQP9, LILRA5, CXCL3, BCL2A1, LILRA6, C19orf59, LIRRB2, CCL18 LYN, CCL20 MEFV, CD300E MMP12, CTSC NCF2, CXCL1 OSM, CXCL2 PLAUR, CXCL3 PTAFR, CXCL5 S100A12, CXCL6 S100A8, CXCR1 S100A9, CXCR2 SERPINB8, EMR2 SLC11A1, EMR3 SOD2, FCGR3B TREM1, FGR, FPR1, GPR97, HCK, HK3, ICAM1, IL15RA, IL1B, IL1R2, IL1R2, IL6, IL2RA, IL8, LILRA3, TREM1 Veglia et al. (2021) | ||
| NSCLC | Lung cancer tissue | IL6, OLR1, and TGFB1 | ||
| MM | BM and PB | ROS, ARG Görgün et al. (2013) | ||
| M-MDSC (Lin− HLA−DR- CD11b+ CD33+ CD14+ | MM | BM and PB | ROS, ARG Görgün et al. (2013) | |
| B-cell non-Hodgkin lymphoma | PB | Arg-1, IL-10, PD-L1 and S100A12 Lin et al. (2011); Tadmor et al. (2013); Khalifa et al. (2014); Wu et al. (2015); Xiu et al. (2015); Azzaoui et al. (2016) | ||
| DLBCL | PB | IL-10 and S100A12 Azzaoui et al. (2016) | ||
| Head and neck cancer | PB | DR5 Condamine et al. (2014) | ||
| Ovarian cancer | Blood, ascites, and tissue | PD-L1 Okła et al. (2020) | PD-L1 Okła et al. (2020) | |
| NSCLC | PB | S100A8, S100A9 Feng et al. (2012) | ||
| Breast cancer | PB | CD84 Alshetaiwi et al. (2020) | WFDC17, CD84, ARG2, IL1B Alshetaiwi et al. (2020) | |
| NSCLC | Lung cancer tissue | IL10, CD14, and VEGFA | ||
| Melanoma | Spleen | IL-6, IL-8, Tobin et al. (2019) | CXCR1 |
NSCLC, Non-Small Cell Lung Cancer; PB, peripheral blood; BM, bone marrow; LOX1, Lectin-like oxidized low-density lipoprotein (LDL) receptor-1; FATP2, Fatty acid transport protein; DR5, Death receptor 5; WFDC17, whey acidic protein-type four-disulfide core domain 17; ARG2, Arginase 2; IL1B, Interleukin-1beta; PTGS2, Prostaglandin-endoperoxide synthase; CSF1, Colony Stimulating Factor 1; IL-8, Interleukin 8; IRF1, Interferon Regulatory Factor 1; IL4R, Interleukin four Receptor; STAT1, Signal transducer and activator of transcription 1; STAT3, Signal transducer and activator of transcription 3; STAT6, Signal transducer and activator of transcription 6; TGFB1, transforming growth factor-beta; AQP9, Aquaporin 9; LILRA5, Leukocyte Immunoglobulin Like Receptor A5; CXCL3, Chemokine (C-X-C motif) ligand 3; BCL2A1, BCL2 Related Protein A1; LILRA6, Leukocyte Immunoglobulin Like Receptor A6; C19orf59, chromosome 19 open reading frame 59; LIRRB2, Leukocyte Immunoglobulin Like Receptor B2; CCL18, C-C Motif Chemokine Ligand 18; LYN, LYN, proto-oncogene; CCL20, C-C Motif Chemokine Ligand 20; MEFV, MEFV, innate immunity regulator, pyrin, MMP12, (Matrix Metallopeptidase 12; CTSC, Cathepsin C; NCF2, Neutrophil Cytosolic Factor 2; OSM, Oncostatin M; PLAUR, plasminogen activator, Urokinase Receptor; PTAFR, platelet activating factor receptor; CXCL5, C-X-C Motif Chemokine Ligand 5; S100A12, S100 Calcium Binding Protein A12; S100A9, S100 Calcium Binding Protein A9; CXCR2, C-X-C Motif Chemokine Receptor 2; SERPINB8, Serpin Family B Member 8; EMR2, EGF-Like Module-Containing Mucin-Like Hormone Receptor-Like 2); SLC11A1, Solute Carrier Family 11A Member 1; EMR3, EGF-like module-containing mucin-like hormone receptor-like 3; SOD2, Superoxide Dismutase 2; FCGR3B, Fc Gamma Receptor IIIb; TREM1, Triggering Receptor Expressed On Myeloid Cells 1; FGR, FGR, Proto-Oncogene, Src Family Tyrosine Kinase; FPR1, Formyl peptide receptor 1; GPR97, G protein-coupled receptor 97; HCK, HCK, Proto-Oncogene, Src Family Tyrosine Kinase; HK3, Hexokinase 3; ICAM1, Intercellular Adhesion Molecule 1; IL15RA, Interleukin 15 Receptor Subunit Alpha; IL1B, Interleukin-1beta; IL1R2, Interleukin one Receptor Type 2; IL6, Interleukin 6; IL2RA, Interleukin two Receptor Subunit Alpha; LILRA3, Leukocyte Immunoglobulin Like Receptor A3; TREM1, Triggering Receptor Expressed On Myeloid Cells 1; TGFB1, Transforming Growth Factor Beta 1; ROS, Reactive oxidation species; ARG, Arginase; DLBCL, Diffuse large B-cell lymphoma; MM, multiple myeloma.